Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Otsuka Backs Up Tolvaptan Data In Polycystic Kidney Disease

Executive Summary

Further top-line results from a Phase III study have been promising, and the US FDA will have to decide if the previously rejected polycystic kidney additional indication for tolvaptan is now firmly supported by safety and efficacy data.

You may also be interested in...



Keeping Track: Good News/Bad News For Pfizer; Filings For Brexanolone, Risankizumab

The latest US drug development news and highlights from our Performance Tracker.

Pipeline Watch: Top-Line Ozanimod, Romosozumab, Cariprazine Phase III Results

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Peptomyc Battles Cancer R&D Conventions

Laura Soucek, one of In Vivo’s 2020 Rising Leaders, is hoping to take Barcelona-based start-up Peptomyc to the next level. The company is nearing the clinic with an inhibitor of the transcription factor Myc, which is involved in the regulation of cellular proliferation, but can also be a driver of cancer.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132327

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel